Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?

IF 6.7 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-08-13 DOI:10.1111/apt.70323

C C Mark Cheah, B B George Goh

引用次数: 0

查看原文本刊更多论文

评论：代谢功能障碍相关脂肪变性肝病（MASLD）伴晚期纤维化也等同于晚期冠状动脉疾病的风险吗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.